Sanofi reinforces senior staff with two new execs

pharmafile | February 6, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi 

Sanofi has reinforced its senior staff with a double-whammy of appointments; firstly, the French firm has announced that it is bringing Hugo Fry (pictured) to the position of General Manager for the UK and General Manager, Sanofi Pasteur in the UK and Ireland. Secondly, Dr Hubert Bland will be stepping into the role of Medical Head of Diabetes and Cardiovascular for UK and Ireland.

Fry has more than 20 years of experience in the pharmaceutical industry, having served companies including Sanofi Pasteur MSD where he held the position of Chief Marketing Officer and was a key part of the European Vaccine Joint Venture.

“I am honoured to be appointed as General Manager for the UK,” Fry remarked. “I am proud and motivated to lead our more than 1,800 UK colleagues, who continuously demonstrate their commitment to serving the people whose lives we touch. Our ambition in the UK is to be a partner in improving the nation’s health. We are dedicated to leveraging the unique diversity of our portfolio and strength of our pipeline to empower people to live life to the fullest.”

Bland previously worked at TMC Pharma as its Vice President of Medical and served in medical leadership roles at Pfizer, Boehringer Ingelheim, Linde and the University of Surrey’s Clinical Research Centre.

Bland added: “The UK healthcare system is under constant pressure therefore the demand for new and effective treatments, services and solutions is ever-increasing. An effective medical function within Sanofi is vital to ensure we are there for people in the moments that matter. I am committed to leading a team that functions at the highest level of quality standards and adds significant value to healthcare professionals and other relevant stakeholders on behalf of Sanofi in the UK.”

Related Content

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …

Sanofi shares new data for long-term efficacy of Nexviazyme for Pompe disease treatment

Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the …

Janssen and Sanofi enter agreement for potential vaccine programme

Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …

Latest content